0001182489-17-000451.txt : 20170802 0001182489-17-000451.hdr.sgml : 20170802 20170802160951 ACCESSION NUMBER: 0001182489-17-000451 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170731 FILED AS OF DATE: 20170802 DATE AS OF CHANGE: 20170802 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PATEL RAJIV A CENTRAL INDEX KEY: 0001275110 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36828 FILM NUMBER: 17999991 MAIL ADDRESS: STREET 1: C/O FARALLON CAPITAL MANAGEMENT, L.L.C. STREET 2: ONE MARITIME PLAZA, SUITE 2100 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nexvet Biopharma plc CENTRAL INDEX KEY: 0001618561 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK STREET 2: RAHAN ROAD CITY: TULLAMORE , CO. OFFALY STATE: L2 ZIP: R35 FR98 BUSINESS PHONE: 353 1 215 8100 MAIL ADDRESS: STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK STREET 2: RAHAN ROAD CITY: TULLAMORE , CO. OFFALY STATE: L2 ZIP: R35 FR98 FORMER COMPANY: FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd DATE OF NAME CHANGE: 20140903 4 1 edgar.xml FORM 4 - X0306 4 2017-07-31 1 0001618561 Nexvet Biopharma plc NVET 0001275110 PATEL RAJIV A C/O FARALLON CAPITAL MANAGEMENT, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO CA 94111 1 0 0 0 Ordinary Shares 2017-07-31 4 D 0 13580 6.72 D 0 D Restricted Share Units 2017-07-31 4 D 0 1000 6.595 D Ordinary Shares 1000 0 D Each Restricted Share Unit ("RSU") is convertible into one ordinary share of the Issuer upon vesting, subject to payment by the holder to the Issuer of the nominal value per share ($0.125). The 1,000 RSUs held by Patel were scheduled to vest and become convertible in quarterly installments of 500 on September 30, 2017 and December 31, 2017. Such RSUs were canceled in the Acquisition, as described below. Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). These RSUs, which were not yet vested, were cancelled in the Acquisition in exchange for a total cash payment equal to $6,595, representing the difference between the conversion payment of $0.125 per RSU and the $6.72 consideration per ordinary share payable in connection with the Acquisition, multiplied by the 1,000 ordinary shares issuable upon the vesting and conversion of such RSUs. Effective July 31, 2017, Patel resigned as a director of the Issuer upon the consummation of the Acquisition. /s/ Rajiv A. Patel 2017-08-02